LICHENOID DRUG ERUPTION ASSOCIATED WITH IMATINIB MESYLATE: TWO CASES

Özet

Abstract

Atatürk University Medical Faculty, Departments of Internal Medicine1, Dermatology2 and Pathology3, Erzurum, Turkey Imatinib mesylate (STI571) is a new therapeutic agent which inhibits the tyrosine kinase of the BCR-ABL, c-kit and platelet derived growth factor oncogenes. It is used for the treatment of chronic myelogenous leukemia, Philadelphia chromosome positive acute lymphoblastic leukemia and gastrointestinal stromal tumors. Although, cutaneous side effects of this drug is common, lichenoid eruption is exceptional. We report two cases of disseminated lichenoid cutaneous reaction, which developed in two patients with chronic myelogenous leukemia treated with imatinib mesylate